The therapeutic application of Distraneurin (Clomethiazole) generally focuses on providing supportive symptomatic relief and significant sedation in acute clinical settings. Its primary uses are established for specific domains marked by heightened neurological or muscular activity and significant patient distress.

This medication is commonly applied across conditions presenting with acute episodes where short-term symptomatic assistance is needed. Its primary therapeutic domains include the management of Alcohol Withdrawal Syndrome, the relief of severe psychomotor agitation and restlessness, and the short-term treatment of severe insomnia in appropriate patient groups. It is applied in managing intense physical and mental symptoms related to hyperexcitability, such as severe agitation, restlessness, anxiety, and tremors.

The primary benefit is in providing supportive relief to assist the patient during phases of extreme distress and heightened physiological activity.

The medication assists in easing the impact of these disruptive manifestations, offering a state of significant relaxation and contributing to improved day-to-day comfort during severe, high-symptom episodes. Its use is relevant in clinical settings that involve unstable symptom patterns, helping manage the functional strain caused by prolonged sleeplessness or intense agitation.

---

Quick Fact: Support for Symptomatic Discomfort

Distraneurin is relevant when symptoms become temporarily overwhelming, providing support that helps ease the overall symptom burden in situations involving heightened neurological activity.

Who can and cannot use Distraneurin?

The eligibility profile for Distraneurin (Clomethiazole) is strictly defined by regulatory documents, distinguishing between groups permitted to use the medicine and those who are absolutely restricted or require conditional use. The medicine is primarily for use in adults who do not meet any exclusion criteria.

Contraindicated Populations (Must Not Use)

Distraneurin is contraindicated and must not be used by patients with acute pulmonary insufficiency or a known hypersensitivity to clomethiazole or its components. Furthermore, it is strongly discouraged for alcoholics who continue to consume alcoholic beverages.

Restricted and Conditional Use

Use is not recommended for children and adolescents under 18 years, as safety and efficacy have not been established in this age group. The medicine should not be used in pregnancy, especially during the first and last trimesters, due to a lack of safety evidence. Use during breastfeeding is restricted to cases where the benefit outweighs the hazard.

Mandatory Caution is required for patients with certain pre-existing conditions, including gross liver damage, chronic renal disease, chronic pulmonary insufficiency, or sleep apnoea syndrome. Great caution is also mandatory for older adults and patients with a history of alcohol or drug dependence.

Interactions with other medicines and products

Official regulatory documents define the interaction profile of clomethiazole (Distraneurin) by strict restrictions and documented pharmacokinetic changes with co-administered substances. Co-administration of alcohol (alcoholic beverages) is formally contraindicated due to the risk of fatal respiratory depression, with this risk being specifically noted as heightened in patients with liver cirrhosis.

Clomethiazole should not be used with other centrally acting depressant drugs, including Benzodiazepines, as this combination may result in pharmacodynamic potentiation that can lead to severe outcomes like cardiorespiratory collapse.

Exposure-altering interactions are also documented. Cimetidine inhibits the metabolism of clomethiazole, potentially causing increased plasma concentrations. Conversely, enzyme inducers like Carbamazepine increase the clearance of clomethiazole, leading to decreased plasma concentrations. Other substances noted in regulatory labels include Propranolol, which may have altered bioavailability, and Diazoxide, a combination that should be avoided due to risks associated with maternal administration. No mandatory timing-based separation rules are explicitly documented.

The Mechanism of Clomethiazole

Distraneurin, containing the active substance clomethiazole, functions primarily as a positive allosteric modulator of the GABA-A receptor complex in the central nervous system (CNS). This receptor complex is the main site for the activity of gamma-aminobutyric acid (GABA), the principal inhibitory neurotransmitter in the brain.

Clomethiazole binds to a distinct site on the GABA-A receptor—often associated with the barbiturate/picrotoxin site—which is separate from the binding site of the endogenous GABA molecule. This molecular interaction enhances the response of the receptor to GABA, resulting in an increased frequency and/or duration of chloride ion (Cl-) channel opening . The subsequent influx of negatively charged chloride ions into the postsynaptic neuron leads to hyperpolarization of the neuronal membrane.

This hyperpolarization decreases the excitability of the neuron, resulting in a systemic physiological modulation of CNS activity characterized by generalized neuronal depression and reduced propagation of electrical signals throughout the neural network. A secondary action involves the inhibition of the cytochrome P450 enzyme CYP2E1.

How to Use Distraneurin (Clomethiazole)

The usage of Distraneurin involves specific routes of administration and structured dosing protocols. Clomethiazole is available for oral use as soft capsules (192 mg) and syrup, and for intravenous (IV) infusion as an 0.8% solution.

---

Official Administration and Dosing

The regimen for Clomethiazole, particularly for acute conditions, follows a time-limited, tapering structure.

Indication (Adults)	Typical Dosing Structure	Frequency & Duration
Acute Alcohol Withdrawal	The initial daily dose is high, typically 9 to 12 capsules (1,728 mg to 2,304 mg) on Day 1, which is then gradually reduced over subsequent days.	Total daily dose is divided and administered 3 or 4 times a day. Treatment is limited to a maximum of 9 days.
Agitation (Elderly)	1 capsule (192 mg) per dose.	Administered three times daily.
Severe Insomnia (Elderly)	1 to 2 capsules (192 mg to 384 mg).	Administered once daily, before going to bed.

---

Administration Requirements

Administration involves specific procedural constraints and setting requirements. Oral capsules must be swallowed whole with water and are not to be broken, crushed, or chewed. Treatment for acute alcohol withdrawal often requires close monitoring in a hospital setting. During dosage titration, the administered amount must be adjusted to keep the patient sedated but rousable.

Population-Specific Use

For older adults, the lowest effective dose should be prioritized, particularly for the insomnia indication. The product is not recommended for use in children and adolescents under 18 years of age due to a lack of established data. Patients with hepatic impairment may experience a decreased elimination rate, necessitating caution in dose adjustment.

Research Evidence / Overview of Studies for Distraneurin

Official summaries show that the research evidence for the active ingredient, Clomethiazole, is drawn primarily from controlled clinical studies and reviews that explore its short-term use in specific acute clinical situations. The findings describe group patterns and reflect the specific conditions under which the studies were conducted.

---

Evidence for Use in Acute Alcohol Withdrawal Syndrome

The majority of evidence for the use of Clomethiazole in acute alcohol withdrawal syndrome (AWS) comes from controlled clinical trials and subsequent systematic reviews. These studies were conducted during periods of increased symptom activity in adults admitted to hospital settings. Researchers examined outcomes related to acute symptom changes, tracking measures such as overall clinical severity scores and monitoring for specific outcomes related to seizure occurrence.

Findings describe patterns observed in these studies, which compared Clomethiazole using both inactive treatments (placebo) and other active treatments for AWS. The methodologies of some older foundation studies were observed to be heterogeneous, which may introduce variability across the data set. Comparative evidence against many other agents remains limited, contributing to uncertainty in the broader research landscape.

---

Evidence for Use in Severe Insomnia

Research for Clomethiazole was conducted in trials exploring severe insomnia, primarily through short-term trials and subsequent meta-analyses. The evidence base primarily involves studies in older adults (typically aged 60 years and above). These studies monitored specific outcomes related to functional imbalance, such as Total Sleep Time and the subjective assessment of sleep quality.

Studies reported changes measured during the study period, where findings describe patterns related to total sleep duration and patient-reported sleep quality when Clomethiazole was studied against placebo in older adults. A key research limitation is that the results apply primarily to the populations studied: older adults. Follow-up durations were limited, meaning there is limited information for long-term outcomes for patients with chronic insomnia. Data for younger adult populations are still emerging or not available.

Common questions about Distraneurin (FAQ)

---

Q: How quickly can I expect Distraneurin to start working?

Official product information, based on pharmacokinetic studies, indicates that the active ingredient reaches its highest concentration in the bloodstream fairly quickly. After taking the soft capsules, this peak is typically achieved within 30 to 60 minutes.

---

Q: How long does the effect of Distraneurin typically last in the body?

Studies examining how the body handles the medicine provide information on its duration. The elimination half-life of the active substance is reported to be around 4 to 5 hours, which is the time required for half of the medicine to be cleared from the body.

---

Q: Is it common to feel tired the day after taking Distraneurin?

Regulatory information indicates that a feeling of being excessively tired or groggy, sometimes referred to as a 'hangover' effect, may occur. This is particularly noted as a consideration for older adults using the medicine.

---

Q: Is it safe to drive or operate machinery while taking Distraneurin?

Due to its function as a Central Nervous System (CNS) depressant, this medicine can cause excessive sedation and impaired concentration. Official documentation warns that these effects can seriously affect a person’s ability to safely operate machinery or vehicles. Regulatory warnings typically indicate that individuals should assess the risk and exercise caution with activities requiring mental alertness.

---

Q: What are the signs of an allergic reaction to Distraneurin?

Severe allergic reactions, known as anaphylaxis, are rare but serious risks documented in the product information. Signs can include a sudden onset of a rash, itching, hives, or blistering of the skin. More severe symptoms involve swelling of the face, lips, or tongue, or difficulty with breathing.

---

Q: Can Distraneurin interact with common pain relief medications?

Official warnings state that the medicine should not be combined with any other centrally acting depressant drugs, as this can lead to severe outcomes like cardiorespiratory collapse. Some common pain or cold medicines available over-the-counter may contain these depressants. Information regarding the use of other medicines is provided in the official warnings.

---

Q: What common over-the-counter cold medicines might interact with Distraneurin?

Regulatory documents caution against the concurrent use of Distraneurin with any other centrally acting depressant drugs due to the high risk of potentiation. This safety constraint means certain over-the-counter (OTC) cold or allergy medicines that cause drowsiness may pose an interaction risk, and the potential for adverse events in combination is described in the labeling.

---

Q: What is the difference between how Distraneurin works and how traditional sedatives work?

The active substance, clomethiazole, is classified as a non-benzodiazepine sedative. Its mechanism of action is unique because it works by binding to a distinct site on the GABA-A receptor complex in the brain. This site is often associated with the barbiturate/picrotoxin binding site, which is physically separate from where many traditional sedatives, like benzodiazepines, attach.

---

Q: Does Distraneurin affect blood pressure or heart rate?

Official studies have examined the physiological effects of the medicine during administration. Findings have described a prominent temporary increase in pulse rate (heart rate). However, blood pressure was generally observed to remain stable during the studies.

---

Q: If someone is taking an antidepressant, can they also take Distraneurin?

Official interaction labels list specific antidepressants, such as Amitriptyline, as substances where co-administration can increase the risk or severity of Central Nervous System (CNS) depression. The potential for increased risk in this combination is described in the product labeling.

---

How to Store and Dispose of Distraneurin (Clomethiazole)

Official regulatory documents mandate specific storage and disposal requirements for Distraneurin (Clomethiazole) to preserve its stability and ensure safety.

Mandatory Storage Conditions

Requirement	Official Instruction
Temperature	Must not be stored above 25 C (Controlled Room Temperature).
Protection	Keep in the original container and protect from light and moisture.
Container	The container must be kept tightly closed where applicable.
Child Safety	Must be kept out of the sight and reach of children.

Official Disposal Instructions

Unused or expired Distraneurin must not be thrown away via wastewater or household waste, as this violates environmental protection regulations. The official instruction is to ask the pharmacist how to throw away medicines that are no longer required.